Citations

Clear

590 citation(s) found for "Ho, Ben".

Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin
Fontana, Elisa , Meyers, Jeff, Sobrero, Alberto F. , Iveson, Timothy , Shields, Anthony F., Taı̈eb, Julien , Yoshino, Takayuki , Souglakos, Ioannis, Smyth, Elizabeth C., Lordick, Florian, Moehler, Markus , Giraut, Anne, Harkin, Andrea , Labianca, Roberto, Meyerhardt, Jeffrey, Boukovinas, Ioannis , Saunders, Mark, Vernerey, Dewi, Georgoulias, Vassilis, Ben‐Aharon, Irit , Shi, Qian , Meyerhardt, Jeffrey A. , Sobrero, Alberto , André, Thierry , Boukovinas, Ioannis , Lonardi, Sara , Oki, Eiji , Ben-Aharon, Irit , Shi, Qian , Meyerhardt, Jeffrey A , Iveson, Timothy J , Yoshino, Takayuki , Taieb, Julien , Fontana, Elisa , Meyers, Jeff, Shields, Anthony F., Souglakos, Ioannis, Smyth, Elizabeth C., Lordick, Florian, Moehler, Markus , Giraut, Anne, Harkin, Andrea , Labianca, Roberto, Saunders, Mark, Vernerey, Dewi, Georgoulias, Vassilis

Mayo Clinic

Journal of Clinical Oncology | November 9, 2021 | Volume: 39 | Issue: 36 | Pages: 4009-4019

10.1200/jco.21.02008 | PMID 34752136 Get It

PURPOSE Early-onset (EO) colorectal cancer (CRC, age < 50 years) incidence is increasing. Decisions on optimal adjuvant therapy should consider treatment adherence, adverse events, and expected outcomes in a population with life expectancy longer than later-onset (LO) CRC (age ≥ 50 years). MATERIALS AND METHODS Individual patient data from six trials in the International Duration Evaluation of Adjuvant Chemotherapy database were analyzed. Characteristics, treatment adherence, and adverse events in stage II or III EO-CRC and LO-CRC were compared. To reduce confounders of non–cancer-related deaths because of age or comorbidities, time to recurrence (3-year relapse-free rate) and cancer-specific survival (5-year cancer-specific mortality rate) were considered. RESULTS Out of 16,349 patients, 1,564 (9.6%) had EO-CRC. Compared with LO-CRC, EO-CRC had better performance status (86% v 80%, P < .01), similar T stage (% T1-3/T4: 76/24 v 77/23, P = .97), higher N2 disease rate (24% v 22%, P < .01), more likely to complete the planned treatment duration (83.2% v 78.2%, P < .01), and received a higher treatment dose intensity, especially with 6-month regimens. Gastrointestinal toxicity was more common in EO-CRC; hematologic toxicity was more frequent in LO-CRC. Compared with LO-CRC, significantly worse cancer-specific outcomes were demonstrated especially in high-risk stage III EO-CRC: lower 3-year relapse-free rate (54% v 65%; hazard ratio [HR] 1.33; 95% CI, 1.14 to 1.55; P value < .001) and higher 5-year cancer-specific mortality rate (24% v 20%; HR 1.21; 95% CI, 1.00 to 1.47; P value < .06). In this subgroup, no difference was observed with 3 or 6 months of therapy, with equally poor disease-free survival rates (57% v 56%; HR 0.97; 95% CI, 0.73 to 1.29; P value = .85). CONCLUSION Young age is negatively prognostic in high-risk stage III CRC and associated with significantly higher relapse rate; this is despite better treatment adherence and higher administered treatment intensity, suggesting more aggressive disease biology.
PMO-31 Rapidity of ulcerative colitis symptom improvements during filgotinib induction: phase 2b/3 SELECTION study post-hoc analysis
Morison, Ben, Hibi∥, Toshifumi , Ritter, Timothy E., Dinoso, Jason B., Hsieh, Jeremy, Yun, Chohee , Zhao, Sally, Danese, Silvio , Zhang, Jie , Loftus, Edward V. , Rogler, Gerhard

Mayo Clinic

Posters | November 7, 2021 | Volume: No volume available | Issue: No issue available | Pages: A93.1-A93

10.1136/gutjnl-2021-bsg.170 Get It

PMO-30 Corticosteroid-free remission of ulcerative colitis with filgotinib maintenance therapy: post-hoc analysis of the SELECTION study
Morison, Ben, Vermeire, Séverine , Feagan, Brian, Yun, Chohee , Hsieh, Jeremy, Liu, Xiaopeng, Zhao, Sally, Moerch, Ulrik, Sandborn, William J. , Hibi∥, Toshifumi , Vermeire, Séverine , Loftus, Edward V.

Mayo Clinic

Posters | November 7, 2021 | Volume: No volume available | Issue: No issue available | Pages: A92.2-A92

10.1136/gutjnl-2021-bsg.169 Get It

OMO-3 Safety analysis of filgotinib for ulcerative colitis: Phase 2b/3 selection study and long-term extension results
Morison, Ben, Watanabe, Mamoru , Yun, Chohee , Zhao, Sally, Hsieh, Jeremy, Moerch, Ulrik, Schreiber, Stefan , Zhou, Yan, Rogler, Gerhard , Loftus, Edward V.

Mayo Clinic

Oral | November 7, 2021 | Volume: No volume available | Issue: No issue available | Pages: A6.1-A6

10.1136/gutjnl-2021-bsg.10 Get It

Acute kidney injury in patients treated with immune checkpoint inhibitors
Short, Samuel , Sise, Meghan E. , Prosek, Jason, Madhavan, Sethu M. , Soler, María José , Ostermann, Marlies , Abudayyeh, Ala , Anand, Shuchi , Motwani, Shveta S. , Murakami, Naoka , Wanchoo, Rimda, Ortiz-Melo, David I. , Rashidi, Arash , Aggarwal, Vikram , Malik, Abhinav , Loew, Sebastian, Carlos, Christopher A., Chang, Wei‐Ting , Beckerman, Pazit , Mithani, Zain, Renaghan, Amanda DeMauro , Seigneux, Sophie de , Campedel, Luca , Shin, Daniel Sanghoon , Rangarajan, Sunil , Deshpande, Priya , Coppock, Gaia, Eijgelsheim, Mark, Lee, Meghan , Husain, Marium , García-Carro, Clara , Bermejo, Sheila , Lumlertgul, Nuttha , Seylanova, Nina , Flanders, Lucy , Isik, Busra , Mamlouk, Omar , García, Pablo , Kaghazchi, Aydin , Khanin, Yuriy, Kansal, Sheru, Wauters, Els , Chandra, Sunandana , Hsu, Raymond K. , Tio, Maria Clarissa , Mothi, Suraj Sarvode, Singh, Harkarandeep , Reynolds, Kerry L. , Cortazar, Frank B. , Leaf, David E. , Salem, Joe‐Elie , Gupta, Shruti , Kitchlu, Abhijat , Lee, Meghan D , Mamlouk, Omar , Lin, Jamie S , Leaf, David E , Murakami, Naoka , Soler, Maria Jose , Salem, Joe-Elie , Hsu, Raymond K , Ostermann, Marlies , Koessler, Thibaud , Gupta, Shruti , Herrmann, Sandra M. , Glezerman, Ilya G , Sprangers, Ben , Malik, A Bilal, Shah, Chintan V , Kitchlu, Abhijat , Seethapathy, Harish Shanthanu , Strohbehn, Ian A. , Owen, Dwight H , Schmidt-Ott, Kai Martin , Schrag, Deborah , Jhaveri, Kenar D.

Mayo Clinic

Journal for ImmunoTherapy of Cancer | October 10, 2021 | Volume: 9 | Issue: 10 | Pages: e003467

10.1136/jitc-2021-003467 | PMID 34625513 Get It

Background Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer. Methods We collected data on 429 patients with ICPi-AKI and 429 control patients who received ICPis contemporaneously but who did not develop ICPi-AKI from 30 sites in 10 countries. Multivariable logistic regression was used to identify predictors of ICPi-AKI and its recovery. A multivariable Cox model was used to estimate the effect of ICPi rechallenge versus no rechallenge on survival following ICPi-AKI. Results ICPi-AKI occurred at a median of 16 weeks (IQR 8–32) following ICPi initiation. Lower baseline estimated glomerular filtration rate, proton pump inhibitor (PPI) use, and extrarenal immune-related adverse events (irAEs) were each associated with a higher risk of ICPi-AKI. Acute tubulointerstitial nephritis was the most common lesion on kidney biopsy (125/151 biopsied patients [82.7%]). Renal recovery occurred in 276 patients (64.3%) at a median of 7 weeks (IQR 3–10) following ICPi-AKI. Treatment with corticosteroids within 14 days following ICPi-AKI diagnosis was associated with higher odds of renal recovery (adjusted OR 2.64; 95% CI 1.58 to 4.41). Among patients treated with corticosteroids, early initiation of corticosteroids (within 3 days of ICPi-AKI) was associated with a higher odds of renal recovery compared with later initiation (more than 3 days following ICPi-AKI) (adjusted OR 2.09; 95% CI 1.16 to 3.79). Of 121 patients rechallenged, 20 (16.5%) developed recurrent ICPi-AKI. There was no difference in survival among patients rechallenged versus those not rechallenged following ICPi-AKI. Conclusions Patients who developed ICPi-AKI were more likely to have impaired renal function at baseline, use a PPI, and have extrarenal irAEs. Two-thirds of patients had renal recovery following ICPi-AKI. Treatment with corticosteroids was associated with improved renal recovery.
Climbing Up and Down Binding Landscapes through Deep Mutational Scanning of Three Homologous Protein–Protein Complexes
Heyne, Michael , Shirian, Jason , Cohen, Itay , Papo, Niv , Shifman, Julia M. , Radisky, Evette S. , Papo, Niv , Shifman, Julia M , Peleg, Yoav

Mayo Clinic

Journal of the American Chemical Society | October 6, 2021 | Volume: 143 | Issue: 41 | Pages: 17261-17275

10.1021/jacs.1c08707 | PMID 34609866 Get It

Radial strain imaging-guided lead placement for improving response to cardiac resynchronization therapy in patients with ischaemic cardiomyopathy: the Raise CRT trial
Glikson, Michael , Beinart, Roy , Golovchiner, Gregory , Sheshet, Alon Bar, Bolous, Munther, Rosso, Raphaël , Medina, Aharon , Haim, Moti , Friedman, Paul A. , Khalamaizer, Vladimir, Ben‐Zvi, Shlomit, Klempfner, Robert , Vaturi, Ori, Oh, Jae K. , Ito, Saki , Goldenberg, Ilan , Beinart, Roy , Haim, Moti , Glikson, Michael , Swissa, Moshe , Goldenberg, Ilan

Mayo Clinic

EP Europace | September 30, 2021 | Volume: 24 | Issue: 5 | Pages: 835-844

10.1093/europace/euab253 | PMID 34734227 Get It

Abstract Aims To evaluate the benefit of speckle tracking radial strain imaging (STRSI)-guided left ventricular (LV) lead (LVL) positioning in cardiac resynchronization therapy (CRT) in patients (pts) with ischaemic cardiomyopathy with CRT indication. Methods and results We conducted a prospective randomized controlled trial. Patients were enrolled in nine centres with 2:1 randomization into two groups (guided vs. control). Patients underwent STRSI to identify the optimal LV position from six LV segments at midventricular level. Implantation via STRSI was attempted for recommended segment in the guided group only. Follow-up included echocardiography (6 months) and clinical evaluation (6 and 12 months). The primary endpoint was comparison % reduction in LV end-systolic volume at 6 months with baseline. Secondary endpoints included hospitalizations for heart failure and death, and improvement in additional echocardiographic measurements and quality of life score. A total of 172 patients (115 guided vs. 57 control) were enrolled. In the guided group, 60% of the implanted LV leads were adjudicated to be successfully located at the recommended segment, whereas in the control group 44% reached the best STRSI determined segment. There was no difference between the groups in any of the primary or secondary endpoints at 6 and 12 months. Conclusion Our findings suggest that echo-guided implantation of an LV lead using STRSI does not improve the clinical or echocardiographic response compared with conventional implantation.
Characterization and Outcomes of Hospitalized Children With Coronavirus Disease 2019: A Report From a Multicenter, Viral Infection and Respiratory Illness Universal Study (Coronavirus Disease 2019) Registry
Bhalala, Utpal , Boman, Karen , Kumar, Vishakha K. , Retford, Lynn, Blatz, Allison M. , Dapul, Heda , Sayed, Imran A., Gharpure, Varsha , Irby, Katherine , Sanders, Ronald C., Heneghan, Julia A. , Thomas, Melissa K., Gupta, Manoj , Oulds, Franscene, Arteaga, Grace M. , Levy, Emily R. , Gupta, Neha , Kaufman, Margit, AbdelAty, Amr M. , Shlomovich, Mark , O'Meara, A M Iqbal, Kuehne, Joshua, Menon, Shina , Khandhar, Paras B., Miller, Aaron S., Barry, Suzanne, Danesh, Valerie , Zammit, Kimberly, Stulce, Casey , McGonagill, Patrick W. , Bercow, Asher, Amzuta, Ioana, Gupta, Sandeep , Almazyad, Mohammed , Pierre, Louisdon , Sendi, Prithvi , Ishaque, Sidra , Nawathe, Pooja , Lyons, Patrick G. , Bello, Imam Wada , Ari, Judith Ben, Kovačević, Tanja , Bansal, Vikas, Brinton, John T. , Rk, Kashyap, Bansal, Vikas , Kovačević, Tanja , Tierney, David M. , Polić, Branka , Markić, Joško , Asghar, Muhammad Sohaib , Galet, Colette , Carev, Dominko , Wen, Andy , Karam, Oliver , Bansal, Vikas , Levy, Emily R , Gharpure, Varsha P , Asghar, Muhammad S , Karam, Oliver , Gist, Katja M. , Tripathi, Sandeep , Chiotos, Kathleen , Verma, Sourabh , Bjornstad, Erica C. , Tofil, Nancy M. , Abdelaty, Amr, Medar, Shivanand , Khanna, Ashish , Anderson, Harry L, Akhter, Murtaza , Chen, Catherine , Walkey, Allan J. , Bihorac, Azra , Zimmerman, Jerry J. , Menon, Shina

Mayo Clinic

Critical Care Medicine | August 13, 2021 | Volume: 50 | Issue: 1 | Pages: e40-e51

10.1097/ccm.0000000000005232 | PMID 34387240 Get It

Objectives: Multicenter data on the characteristics and outcomes of children hospitalized with coronavirus disease 2019 are limited. Our objective was to describe the characteristics, ICU admissions, and outcomes among children hospitalized with coronavirus disease 2019 using Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: Coronavirus Disease 2019 registry. Design: Retrospective study. Setting: Society of Critical Care Medicine Viral Infection and Respiratory Illness Universal Study (Coronavirus Disease 2019) registry. Patients: Children (< 18 yr) hospitalized with coronavirus disease 2019 at participating hospitals from February 2020 to January 2021. Interventions: None. Measurements and Main Results: The primary outcome was ICU admission. Secondary outcomes included hospital and ICU duration of stay and ICU, hospital, and 28-day mortality. A total of 874 children with coronavirus disease 2019 were reported to Viral Infection and Respiratory Illness Universal Study registry from 51 participating centers, majority in the United States. Median age was 8 years (interquartile range, 1.25–14 yr) with a male:female ratio of 1:2. A majority were non-Hispanic (492/874; 62.9%). Median body mass index (n = 817) was 19.4 kg/m2 (16–25.8 kg/m2), with 110 (13.4%) overweight and 300 (36.6%) obese. A majority (67%) presented with fever, and 43.2% had comorbidities. A total of 238 of 838 (28.2%) met the Centers for Disease Control and Prevention criteria for multisystem inflammatory syndrome in children, and 404 of 874 (46.2%) were admitted to the ICU. In multivariate logistic regression, age, fever, multisystem inflammatory syndrome in children, and pre-existing seizure disorder were independently associated with a greater odds of ICU admission. Hospital mortality was 16 of 874 (1.8%). Median (interquartile range) duration of ICU (n = 379) and hospital (n = 857) stay were 3.9 days (2–7.7 d) and 4 days (1.9–7.5 d), respectively. For patients with 28-day data, survival was 679 of 787, 86.3% with 13.4% lost to follow-up, and 0.3% deceased. Conclusions: In this observational, multicenter registry of children with coronavirus disease 2019, ICU admission was common. Older age, fever, multisystem inflammatory syndrome in children, and seizure disorder were independently associated with ICU admission, and mortality was lower among children than mortality reported in adults.
Civilian walking blood bank emergency preparedness plan
Holcomb, John B. , Spinella, Philip C. , Apelseth, Torunn Oveland , Butler, Frank K., Cannon, Jeremy W. , Cap, Andrew P., Corley, Jason B., Doughty, Heidi , Fitzpatrick, Michael H., Goldkind, Sara F., Gurney, Jennifer M. , Homer, Mary J. , Jenkins, Donald H. , Moore, Eugene, Ness, Paul M., Schreiber, Martin A. , Shinar, Eilat , Sloan, Steve, Stubbs, James R. , Taylor, Audra L., Ward, Kevin R. , Waltman, Elizabeth, Yazer, Mark H. , Jansen, Jan O , Strandenes, Geir , Stubbs, James R , Yazer, Mark , Spinella, Philip C , Apelseth, Torunn , Holcomb, John B , Cap, Andrew P., Ilstrup, Sarah J. , Jansen, Jan O. , Marques, Marisa B. , O’Connor, Kevin C. , Strandenes, Geir

Mayo Clinic

Transfusion | July 16, 2021 | Volume: 61 | Issue: S1 | Pages: No page available

10.1111/trf.16458 | PMID 34269450 Get It

Abstract Background The current global pandemic has created unprecedented challenges in the blood supply network. Given the recent shortages, there must be a civilian plan for massively bleeding patients when there are no blood products on the shelf. Recognizing that the time to death in bleeding patients is less than 2 h, timely resupply from unaffected locations is not possible. One solution is to transfuse emergency untested whole blood (EUWB), similar to the extensive military experience fine‐tuned over the last 19 years. While this concept is anathema in current civilian transfusion practice, it seems prudent to have a vetted plan in place. Methods and Materials During the early stages of the 2020 global pandemic, a multidisciplinary and international group of clinicians with broad experience in transfusion medicine communicated routinely. The result is a planning document that provides both background information and a high‐level guide on how to emergently deliver EUWB for patients who would otherwise die of hemorrhage. Results and Conclusions Similar plans have been utilized in remote locations, both on the battlefield and in civilian practice. The proposed recommendations are designed to provide high‐level guidance for experienced blood bankers, transfusion experts, clinicians, and health authorities. Like with all emergency preparedness, it is always better to have a well‐thought‐out and trained plan in place, rather than trying to develop a hasty plan in the midst of a disaster. We need to prevent the potential for empty shelves and bleeding patients dying for lack of blood.